TD Cowen raised the firm’s price target on Ceribell (CBLL) to $29 from $20 and keeps a Buy rating on the shares after the company announced that it has received FDA 510(k) clearance for its delirium monitoring solution. The clearance, making its system the first and only U.S.-approved device for delirium screening and monitoring, comes months ahead of expectations and will significantly expand the company’s total addressable market for adult seizure detection, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- Ceribell, Inc. Gains FDA Clearance for Delirium Device
- Ceribell receives FDA 510k clearance for delirium screening, monitoring device
- Ceribell management to meet virtually with BTIG
- Ceribell Gains FDA Clearance for Seizure Detection Algorithm
- Ceribell’s Strategic Expansion and Growth Potential with FDA Clearance for Clarity Algorithm